Portrai key facts
as of Oct 2026- Developer of a spatial transcriptomics platform intended to improve biopsy quality by applying artificial intelligence.
- Portrai is valued at approximately $14.9M as of Oct 2026 (last reported valuation).
- It has raised $14.5M; the latest was Early Stage VC ($9.9M) in Dec 2025.
- Notable investors include Kakao Ventures, BonAngels Venture Partners, Schmidt (South Korea), Stic Alternative, Amgen — 11 tracked in total.
- Status: Privately Held (backing).
Portrai's last reported valuation, Mar 2023. Nothing priced has surfaced since.
- ·The complete investor list: 11 names
- ·Watch Portrai: the Monday email on marks, rounds and moves
Portrai funding rounds
No funding rounds for Portrai are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Portrai
11+Portrai valuation
Portrai's last reported valuation was $14.9 million in Mar 2023. No priced round, secondary trade or fund mark has surfaced since.
Portrai investors
11 investors are on record for Portrai, including Kakao Ventures, BonAngels Venture Partners, Schmidt (South Korea) and Stic Alternative.
About Portrai
Developer of a spatial transcriptomics platform intended to improve biopsy quality by applying artificial intelligence. The company's platform discovers therapeutic targets and explores potential disease indications with high spatial resolution, translates spatial insights into pathophysiology and drug distribution, and develops and validates spatial biomarkers and companion diagnostics, enabling healthcare institutions to enhance precision medicine strategies and therapeutic efficacy.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 15
- Website
- portrai.io/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.